Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Submitted by admin on September 1, 2022 - 10:25am

Source:

BioSpace

News Tags:

Vaxart

clinical trials

vaccines

COVID-19

oral vaccines

Headline:

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

snippet:

Study met primary safety and secondary immunogenicity endpoints
Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects

Search form

You are here

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate